Recent studies suggested that activation of the PRR upregulates profibrotic markers through reactive oxygen species (ROS) formation; however, the exact mechanisms have not been investigated in CD cells. We hypothesized that activation of the PRR increases the expression of profibrotic markers through MAPK-dependent ROS for- 
also triggers phosphorylation of mitogen activated protein kinases/ extracellular regulated kinases 1/2 (MAPK/ERK1/2). [7] [8] [9] Importantly, the actions of PRR have been associated with renal tissue damage 6 ; indeed, rats overexpressing PRR develop glumeruloesclerosis and hyperfiltration. 10, 11 PRR-mediated activation of the MAPK/ERK1/2 pathway upregulates cyclooxygenase-2 (COX-2) expression in cardiac tissues 12 and renal cortex. 11 More recently, we reported that PRR activation by recombinant prorenin stimulates COX-2 expression independently of angiotensin (ANG) II signalling in renal CD cells. 9 We have demonstrated that chronic ANG II infusions increase CD renin and prorenin synthesis and secretion despite the suppression of renin expression in juxtaglomerular cells. [13] [14] [15] [16] [17] In addition, we have
shown that cultured CD cells undergo to epithelial-mesenchymal transition and have induced expression of fibronectin and collagen I after ANG II treatment.
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It has been shown that despite the low plasma renin activity in patients with diabetic nephropathy, high plasma prorenin levels are detected. 19 Furthermore, this is associated with the occurrence of microvascular complications, such as microalbuminuria and retinopathy. 20 Cells exposed to prorenin show upregulation of fibronectin. 21 Prorenin also induces cell proliferation in human umbilical artery smooth muscle cells through reactive oxygen species (ROS) generation and ERK1/2 activation. 22 In kidney proximal tubular cells the activation of PRR by prorenin increases TGF-β1 and α-smooth muscle actin (α-SMA). 23 Clavreul et al., demonstrated that the induced expression of fibrotic genes in non-differentiated human kidney embryonic (HEK) cells is mediated by a Nox4-dependent mechanism 21 indicating a possible role for ROS as a second messenger in cell damage. Indeed, ROS can activate ERK pathway, 24 however the possibility of ROS formation via MAPK/ERK1/2 has not been explored.
High circulating levels of prorenin were described in diabetic patients more than 20 years ago. 19 Induced expression of prorenin in the collecting duct has been observed in diabetic animal models, 25 which is expected to be higher than plasma. This suggest that PRR activation by tubular prorenin might promote the activation of signalling pathways such as MAPK/ERK 1/2 and ROS, which may contribute to tubular fibrosis. The mechanisms by which PRR could regulate the expression of profibrotic factors and its effects on renal CD cells are not fully understood.
In the present study, we hypothesized that PRR activation by recombinant prorenin enhance the expression of profibrotic factors through MAPK-dependent ROS formation in CD cells. To test this hypothesis, M-1 cells were treated with recombinant prorenin with or without antioxidants or MAPK/ERK1/2 pathway inhibition to evaluate the expression of alpha smooth muscle actin (α-SMA), connecting tissue growth factor (CTGF), plasminogen activator inhibitor-1 (PAI-I), fibronectin, collagen I and the effect on fibroblast-like phenotype. Figure 1A shows the identity of western blot bands detected using Figure 1C , some cells express both markers evidencing that they are intercalated cells. Figure 1D ,E shows the presence of PRR (green) in the membrane at different magnifications. Figure 1F shows another co-localization of PRR and NH(3)-specific transporter (Rhcg) a specific marker of A-type intercalated cell. As suggested in previous reports, 26 PRR is detected in plasma membrane but also in a perinuclear location and probably associated to the endoplasmic reticulum.
| RESULTS

| Band identity of prorenin, renin and immunohistochemical localization of PRR in M-1 cells
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| Antioxidants prevented the prorenin-induced ROS formation and upregulation of profibrotic proteins in M-1 cells
Due to M-1 cells express renin and mostly prorenin (Figure 1B) we performed treatments with different doses of recombinant prorenin ( Figure 2A ) and renin ( Figure 2B ) evaluating ROS generation. As shown in Figure 2A , the concentration of DCF (the product of H2DCFDA oxidation) was augmented at prorenin dose of 10 −8
and 10 −6 mol/L (6.0 ± 0.5 and 6.3 ± 0.6 vs 3.9 ± 0.1 nmol/L DCF/ μg total protein, P < .05). Renin caused a modest increase in ROS formation (4.2 ± 0.2 and 4.4 ± 0.3 vs 3.8 ± 0.2 nmol/L DCF/μg total protein, P = non significant, n = 12). Because prorenin is mostly secreted by CD cells 25 and that the affinity of the receptor for renin and prorenin are in the nanomolar range 28 Figure 2C ). We next examined whether prorenin treatment (4 hours) induces the expression of profibrotic proteins through ROS formation. As shown in Figure 3A ,B, prorenin induced the expression of profibrotic markers CTGF (149 ± 12%, P < .05), α-SMA (160 ± 20%, P < .05), and PAI-I (153 ± 13%, P < .05) while PCA prevented this effect. In a similar experiment we evaluated the effect of treatment with two additional antioxidants, trolox C (TLX) a lipophilic antioxidant 31 and ascorbic acid (AA) that acts as a cytoplasmic antioxidant. 32 TLX and AA partially but not significantly suppressed the effect of prorenin when measuring protein ( Figure 4A ,B) and mRNA levels ( Figure 4C ). The results indicate that PRR mediates the upregulation of α-SMA, CTGF and PAI-I via ROS formation at both the cytoplasmic and plasma membrane levels and suggested that p-coumaric acid is more effective at suppressing ROS formation in both compartments. No effects were observed by using antioxidant treatments alone ( Figure 4D ).
| Prorenin treatment increases ERK 1/2 phosphorylation in M-1 cells
To confirm that prorenin treatment increases phosphorylation of ERK 
| MEK inhibition suppresses ROS formation and upregulation of profibrotic markers in M-1 cells
We next evaluated MEK inhibition on prorenin-induced ROS formation and upregulation of profibrotic factors. Figure 6A shows the effect of prorenin and prorenin plus MEK inhibitor PD98059 treatment (4 hours) on ROS formation. MEK inhibition blunted the augmentation of ROS mediated by prorenin (control 3.91 ± 0.12; prorenin 6.2 ± 0.5, P < .05;
prorenin + PD98059 4.6 ± 0.6, nmol/L DCF/μg total protein) indicating that ROS formation depends on MAPK/ERK activation. We next evaluated the behavior of ROS formation every 20 seconds after rapid addition of prorenin or prorenin + PD98059 to the M-1 cells. As shown in Figure 6B MEK inhibition blunted the augmentation of ROS after prorenin treatment, this effect was observed even after 600 seconds.
Finally we evaluated the effect of MEK inhibition on prorenin-induced profibrotic factors. As observed above, prorenin induced the expression of CTGF, α-SMA and PAI-I (149 ± 12%; 160 ± 20%; 153 ± 13, P < .05)
while MEK inhibition blunted this response ( Figure 7A ,B). No significant effects were observed with PD98059 alone (data not shown).
| PRR mediates the upregulation of α-SMA, CTGF and PAI-I
To knockdown the expression of PRR, M-1 cells were transfected with GFP-shRNA-PRR ( Figure 8A ). In our hands, we obtained near 43% reduction in full length plus soluble forms of PRR protein ( Figure 8B ) as compared to non-transfected cells (43 ± 5% vs 100 ± 9%, P < .05). No effects on PRR expression were observed by using scrambled shRNA. No effects were observed in cell viability after transfections ( Figure 8C ). Using this strategy we were able to partially prevents prorenin-induced ROS Figure 8D ) and the induction of profibrotic markers CTGF (125 ± 12%, P = .039 vs control 100 ± 6%), α-SMA (113 ± 8% vs control: 100 ± 9% P = non significant vs control), and PAI-I (123 ± 11%, control 100 ± 9% P = non significant vs control, Figure 8E ).
| Prorenin-mediated upregulation of profibrotic factors Collagen I, fibronectin and induced fibroblastlike phenotype is mediated by PRR activation through ERK 1/2-dependent ROS formation
Because augmented expression of collagen I and fibronectin is associated with epithelial-mesenchymal transition, 33, 34 we evaluated the expression of both markers after 16 hours of prorenin treatment with or without ROS inhibition, PD98059 or PRR knockdown. Prorenininduced collagen I (170 ± 20%, P < .05 vs control) and fibronectin (198 ± 40%, P < .05 vs control), protein expression were effectively prevented by PCA (98 ± 23% and 100 ± 20%, P = non significant vs control) and MEK inhibitor PD98059 (102 ± 11% and 109 ± 20%, P = non significant vs control). Transfections with shRNA-PRR were able to partially reduce prorenin-induced collagen I and fibronectin protein expression (143 ± 26% and 134 ± 23%, respectively, P < .05
vs Prorenin group). Figure 9A shows a summary of these results in a representative western blot (n = 6). We next evaluated whether vs 10 ± 23%, P < .05), MEK inhibitor PD98059, PCA prevented this effect (15 ± 3% and 13 ± 5%, respectively, P = non significant vs control group), while PRR-shRNA partially reduced the effect (34 ± 8%, P < .05 vs control group).
| DISCUSSION
The present findings demonstrate that PRR activation by recombinant with an affinity in the nanomolar range and its capacity to activate MAPK/ERK1/2 are particularly important facts that might help to understand its role in the development of renal damage and diabetic nephropathy. 37, 38 We have detected the expression of PRR in M-1 at the expected size (38 kDa) we also observed a 25 kDa, which probably correspond to the soluble form of the PRR (sPRR) and the truncated form of 8.9 kDa. As shown in Figure 1 , M-1 cells express mostly prorenin at basal conditions. This agrees with our previous reports showing that prorenin is the most prominent form in intracellular and extracellular media. 39 It is also possible that higher basal levels of secreted prorenin by these cells may add further effects to the added recombinant prorenin in each treatment. High prorenin levels can be observed in pathological conditions. Despite the low levels of plasma renin in patients with diabetic nephropathy, the high levels of plasma prorenin found in these patients are associated with the occurrence of microvascular complications, microalbuminuria and retinopathy. 19, 20 Furthermore, normal concentrations of plasma prorenin are usually 10 times higher than renin and became even higher in diabetic patients. 40 Thus, it is possible that augmented plasma prorenin may interact with CD PRR as it has already been confirmed in animal models of diabetic disease. 25 Furthermore, PRR expression is augmented in podocytes and tubular segments when diabetic nephropathy is present. Additionally, we have shown that not only PRR but also prorenin and renin expression is augmented in the CD of hypertensive animals. 14, 15, 17, 41 Direct association of PRR and kidney damage has been reported. 9 We also demonstrated that PRR activation by nanomolar concentrations of recombinant prorenin was able to induce COX-2 expression in CD intercalated cells in primary cultures 9 as observed in glomeruli.
10,11
Additionally we demonstrated that PRR is expressed in M-1 CD cells specifically in AE-1 expressing cells, confirming the expression of PRR only in intercalated cells ( Figure 1D ) and particularly in an intracellular perinuclear location, with only a minor portion on the cell surface.
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Accumulated evidence indicates that in hypertensive models of ANG II-dependent hypertension there is an increased expression of prorenin and renin in the CD. [13] [14] [15] [16] [17] We have previously shown that renal PRR is also increased, and that there is a time dependent pattern of expression of PRR and COX-2 during chronic ANG II infusion. 41 Then, it is possible that increased prorenin synthesis and secretion by principal cell may interact with PRR in the neighborintercalated cell in the CD to promote activation of MAP/ERK 1/2 cascade independently of ANG II as we show previously. 9 Although divergence of angiotensinogen mRNA transcription and angiotensinogen protein synthesis and metabolism has been reported in different segments of the normal rat proximal tubules, 46 it is also possible that gene expression of angiotensinogen might be present in other nephron segments, suggesting that an ANG II-dependent pathway cannot be avoided.
Although overexpression of PRR has not resulted in a significant cardiovascular injury in rats and mice 45, 47 ; high synthesis of intratubular prorenin and renin might reach enough amounts to activate plasma membrane PRR in the CD. Then, prorenin-induced activation of profibrotic synthesis at supra physiological dose might be better prevented by blocking prorenin-PRR binding as suggested before Kinetic for active ROS formation: ROS formation was measured at 20 second intervals using the same approach mentioned above.
For experiments using the MEK inhibitor, cells were treated after 20 seconds of prorenin treatment ( Figure 5 ).
| Measurements of fibronectin, collagen I by Quantitative real-time RT-PCR (qRT-PCR)
qRT-PCR was performed using the TaqMan PCR system. Total RNA 
| Protein expression analysis
Forty micrograms of total protein were used for western blot analysis. Protein expression levels were quantified after immunoblotting 
| Statistics analysis
Each experiment consisted of five independent observations (each well represented an independent observation). Experiments were performed in at least three different cell passages with n = 5 per treatment. Cells were used until passages 10-12. Differences between groups were assessed by one-way ANOVA followed by Tukey's test using the GraphPad Prism software v 5.0 (GraphPad Software, San Diego, CA, USA); P < .05 was considered statistically significant. 
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